Journals / Tıp Araştırmaları Dergisi / 2010 / Cilt: 8 - Sayı: 2

Troid bezi tümörlü hastalarda serum EGF ve VEGF düzeyleri

Serum levels of VEGF and EGF in thyroid gland tumors

Pages
112–115
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, significant differences of VEGF and EGF serum levels can be explained by their very high production by thyroid tumor cells and by their strong effect on the follicular and endothelial cell proliferation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: VEGF and EGF are involved in the pathogenesis of thyroid gland tumors and their growth.
📊
Key Findings & Data:Methods: Using ELISA kits, we measured the concentrations of growth factors in the peripheral blood serum in 20 patients with thyroid gland tumors (10 adenomas, 10 papillary carcinomas) and compared these concentrations with those in healthy people.
💡
Conclusion & Impact:Also, significant differences of VEGF and EGF serum levels can be explained by their very high production by thyroid tumor cells and by their strong effect on the follicular and endothelial cell proliferation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: VEGF and EGF are involved in the pathogenesis of thyroid gland tumors and their growth. We decided to find whether changes in the production of these cytokines by thyroid tumor cells are reflected by changes of their peripheral blood. Methods: Using ELISA kits, we measured the concentrations of growth factors in the peripheral blood serum in 20 patients with thyroid gland tumors (10 adenomas, 10 papillary carcinomas) and compared these concentrations with those in healthy people. Results: We found significantly higher serum levels of VEGF and EGF in patients with thyroid adenoma and papillary carcinoma compared with those in healthy subjects. But, these parameters, we were not different between groups of investigated subjects. Conclusion: Changes in the production of these cytokines by thyroid gland tumor cells are reflected in their peripheral blood levels. Also, significant differences of VEGF and EGF serum levels can be explained by their very high production by thyroid tumor cells and by their strong effect on the follicular and endothelial cell proliferation.

Özet

Amaç: VEGF ve EGF serum düzeyleri troid bezi tümörlerinin patogenezinde ve onların büyümesindde rol oynar. Hipotezimiz tiroid tumor hücreleri tarafından üretilen bu sitokininler periferal kanda düzeylerini yansıttığını savunmaktayız. Metod: ELISA kit kullanarak tiroid bezi kanserli 20 hastanın ve sağlıklı bireylerimizin periferal kanında bu sitokininleri ölçtük. Bulgular: Biz 10 tiroid adenomalı ve 10 tiroid papillar karsinomlu hastaların serum VEGF ve EGF düzeylerini sağlıklı bireylerimize göre, istatiksel olarak yüksek bulduk. Ancak, tiroid adenomlu ve tiroid papillar karsinomlu hastalar arasında ise bu sitokininlerin konsantrasyonları arasında bir fark göremedik. Sonuç: Tirodi bezi tumor hücreleri tarafından bu sitokininlerin üretimindeki değişikliğin peripheral kan düzeylerini yansıttığını düşünmekteyiz. Aynı zamanda VEGF ve EGF serum düzeyeleri arasındaki farklılık, tiroid tumor hücreleri tarafından üretimini yüksek olması şeklinde açıklanabilir ve foliküle ve endoteliyal hücre proliferasyonunu güçlü etkisini vurgulamaktadır.

🔖

Cite This Article

KEMİK, Ö., KEMİK, A. S., PURİSA, S., ADAŞ, M., HASIRCI, İ., DÜLGER, A., TÜZÜN, S. (2010). Troid bezi tümörlü hastalarda serum EGF ve VEGF düzeyleri. Tıp Araştırmaları Dergisi, Cilt: 8 - Sayı: 2, 112–115. https://ajindex.com/articles/361653

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Klener P. Cytokines in internal Medicine. Grada Publishing, Prague, 1997; 260
  2. Sterzl I. Cytokines-structure and function I, II. Diabetologie, metabolism, endokrinologie, 1999; 4: 185-205
  3. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, Shibuya M, Obara T. Vascular endothelial growth factor-C gene expression in papillary and follicular thyroid carcinomas. Surgery 1999; 126: 1056-1062
  4. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M. Expression VEGF in human thyroid neoplasms. Hum Pathol 1999; 30: 891-897
  5. Vesely D, Astl J, Lastuvka P, Matucha P, Sterzl I. Serum levels of IGF-1, HGF, TGFβ1, bFGF and VEGF in thyroid gland tumors. Physiol Res 2004; 53: 83-89
  6. Eggo MC, King W, Black EG, Sheppard MC. Functional human thyroid cells and their IGF binding proteins: regulation by growth factors. J Clin Endocrinol Metab 1996; 81: 3056-3062
  7. Hrda P, Sterzl I, Matucha P. Comparison of cytokine levels in sera of patients with autoimmune endocrinopaties. Physiol Res 2003; 52: 265-267
  8. Sato K, Miyakawa M, Onoda N, demura H, yamashita T, Miura M, et sl. Increased concentrations of vascular endothelial growth factor/vascular permeability factor in cyst fluid of enlarging and recurrent thyroid nodules. J Clin Endocrinol Metab 1997; 82: 1968-1973
  9. Viglietto G, Romano A, Manzo G, Chiappetta G, paoletti I, Califano D, Galati MG, Mauriello V, Bruni P, Lago CT, Fusco A, persico MG. Upregulation of the angiogenic factor PIGF, VEGF and their receptors by TSH in the thyroid gland of thiouracil-fed rats suggests a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 1997; 15: 2687-2698
  10. Katoh R, Miyagi E, Kawaoı A, Hemmi A, Komiyama A, Oyama T, Shibuya M. Expression VEGF in human thyroid neoplasms. Hum Pathol 1999; 30: 891-897.